semaglutide compounding fda enforcement news The growing availability of compounded GLP-1 weight-loss drugs has prompted warnings from doctors and the U.S. Food and Drug Administration. Link in comments⬇️ FDA sets tirzepatide compounding deadlines

One caveat the literature is honest about: as of May 2026, no randomized controlled trial has yet tested resistance training as a counter-measure specifically to GLP-1-induced lean-mass loss

Black, Hispanic, American Indian and Alaska Native, and Native Hawaiian and Pacific Islander adults have higher per capita obesity rates than white adults, they are less likely to have health insurance and more likely to have lower incomes, according to a 2023 analysis from KFF

10:e02566-18

Persistence remains mixed: a 2024 real-world study found 32% on therapy at 1 year among non-diabetic users, and according to Prime Therapeutics, only 1 in 12 remain at 3 years

Crucial for bone health during weight loss

Cannot recommend this site enough